Actinium Pharmaceuticals (ATNM) Lifted to Hold at Zacks Investment Research

Share on StockTwits

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “

A number of other equities analysts have also issued reports on ATNM. B. Riley set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, March 14th. Maxim Group set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, March 28th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $3.70.

Shares of Actinium Pharmaceuticals traded down $0.05, reaching $0.58, on Tuesday, Marketbeat.com reports. The stock had a trading volume of 3,297,987 shares, compared to its average volume of 1,010,593. Actinium Pharmaceuticals has a fifty-two week low of $0.33 and a fifty-two week high of $1.33.

A number of hedge funds have recently made changes to their positions in ATNM. Anson Funds Management LP bought a new position in Actinium Pharmaceuticals during the first quarter worth $1,502,000. Sabby Management LLC bought a new position in Actinium Pharmaceuticals during the first quarter worth $729,000. Sio Capital Management LLC bought a new stake in Actinium Pharmaceuticals in the 1st quarter valued at $393,000. Worth Venture Partners LLC bought a new stake in Actinium Pharmaceuticals in the 1st quarter valued at $140,000. Finally, D.A. Davidson & CO. increased its holdings in Actinium Pharmaceuticals by 227.1% in the 4th quarter. D.A. Davidson & CO. now owns 157,000 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 109,000 shares during the period.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.

Get a free copy of the Zacks research report on Actinium Pharmaceuticals (ATNM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply